Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICRA study of paclitaxel with tremelimumab with or without durvalumab in advanced urothelial cancer
NL-OMON52947Completed
- Sponsor
- Netherlands Cancer Institute
- Start
- May 2019
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised, open-label trial of paclitaxel, tremelimumab and durvalumab in transitional cell carcinoma (TCC) and urinary tract cancer (3 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Objective response rate. Started May 2019; status: completed.
02
Drugs
paclitaxeltremelimumabdurvalumab
03
Conditions
transitional cell carcinoma (TCC)urinary tract cancer
Beyond the preview
Go deeper on NL-OMON52947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52947.